# Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation

> **NCT06138587** · PHASE1 · RECRUITING · sponsor: **Dana-Farber Cancer Institute** · enrollment: 15 (estimated)

## Conditions studied

- Acute Myeloid Leukemia
- Leukemia
- Leukemia, Myeloid
- Myelodysplastic Syndromes
- Myeloproliferative Neoplasm
- Myeloproliferative Disorders

## Interventions

- **BIOLOGICAL:** Cytokine Induced Memory-like Natural Killer Cells
- **BIOLOGICAL:** Interleukin-2

## Key facts

- **NCT ID:** NCT06138587
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-01-24
- **Primary completion:** 2027-02-28
- **Final completion:** 2027-11-30
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2026-01-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06138587

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06138587, "Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06138587. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*